Ruth Ann Subach

962 total citations
20 papers, 768 citations indexed

About

Ruth Ann Subach is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Ruth Ann Subach has authored 20 papers receiving a total of 768 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Physiology. Recurrent topics in Ruth Ann Subach's work include Receptor Mechanisms and Signaling (6 papers), Pain Mechanisms and Treatments (4 papers) and Neuropeptides and Animal Physiology (3 papers). Ruth Ann Subach is often cited by papers focused on Receptor Mechanisms and Signaling (6 papers), Pain Mechanisms and Treatments (4 papers) and Neuropeptides and Animal Physiology (3 papers). Ruth Ann Subach collaborates with scholars based in United States, Japan and United Kingdom. Ruth Ann Subach's co-authors include David G. Soergel, Franck Skobieranda, Michael W. Lark, Jonathan D. Violin, Lynn R. Webster, Brian M. Sadler, Conrad L. Cowan, Ian E. James, Nancy Burnham and Michael E. Kuss and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Neurology.

In The Last Decade

Ruth Ann Subach

20 papers receiving 752 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruth Ann Subach United States	10	490	413	162	125	122	20	768
David Burt United States	10	261 0.5×	237 0.6×	129 0.8×	164 1.3×	165 1.4×	20	567
Marcus F. Brackeen United States	12	253 0.5×	78 0.2×	78 0.5×	176 1.4×	107 0.9×	16	651
J L Valentine United States	15	237 0.5×	147 0.4×	52 0.3×	38 0.3×	98 0.8×	26	560
Jan Pype Belgium	15	207 0.4×	118 0.3×	203 1.3×	26 0.2×	105 0.9×	26	683
Rodolfo Pedro Rothlin Argentina	15	282 0.6×	169 0.4×	120 0.7×	10 0.1×	45 0.4×	42	768
Margarete M. Trachez Brazil	12	118 0.2×	49 0.1×	73 0.5×	61 0.5×	92 0.8×	31	360
Shunji Yamazaki Japan	12	272 0.6×	131 0.3×	103 0.6×	11 0.1×	65 0.5×	20	681
Spencer C. Yost United States	8	262 0.5×	172 0.4×	37 0.2×	47 0.4×	50 0.4×	9	662
Jacob Lund Denmark	14	293 0.6×	96 0.2×	20 0.1×	97 0.8×	526 4.3×	34	1.1k
Karin Tunblad Sweden	13	100 0.2×	58 0.1×	89 0.5×	25 0.2×	25 0.2×	21	502

Countries citing papers authored by Ruth Ann Subach

Since Specialization

Citations

This map shows the geographic impact of Ruth Ann Subach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Ann Subach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Ann Subach more than expected).

Fields of papers citing papers by Ruth Ann Subach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Ann Subach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Ann Subach. The network helps show where Ruth Ann Subach may publish in the future.

Co-authorship network of co-authors of Ruth Ann Subach

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Ann Subach. A scholar is included among the top collaborators of Ruth Ann Subach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Ann Subach. Ruth Ann Subach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Levis, Mark J., Alexander E. Perl, Gary J. Schiller, et al.. (2024). A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood Advances. 8(10). 2527–2535. 9 indexed citations

Langer, Corey J., Brendan D. Curti, Charles M. Farber, et al.. (2024). A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2615–2615. 2 indexed citations

Jankú, Filip, Milind Javle, Shiraj Sen, et al.. (2023). A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors. Cancer. 129(10). 1537–1546. 1 indexed citations

Matulonis, Ursula A., Justin C. Moser, Siqing Fu, et al.. (2022). A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3101–3101. 3 indexed citations

Borazanci, Erkut, Erika Hamilton, Jacob Thomas, et al.. (2022). A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3097–3097. 3 indexed citations

Levis, Mark J., Catherine C. Smith, Alexander E. Perl, et al.. (2021). Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology. 39(15_suppl). 7008–7008. 9 indexed citations

Mahalingam, Devalingam, Vivek Subbiah, Taofeek K. Owonikoko, et al.. (2021). Phase I expansion study of P-cadherin-targeted 90Y-FF-21101 antibody in advanced chemorefractory colorectal and pancreatic-biliary cancers.. Journal of Clinical Oncology. 39(3_suppl). 78–78. 1 indexed citations

Jankú, Filip, Shiraj Sen, Shubham Pant, et al.. (2019). Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3008–3008. 1 indexed citations

Singla, Neil, Harold S. Minkowitz, David G. Soergel, et al.. (2017). A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. Journal of Pain Research. Volume 10(3). 2413–2424. 121 indexed citations

10.

Viscusi, Eugene R., Harold S. Minkowitz, Lynn R. Webster, et al.. (2016). (433) Rapid reduction in pain intensity with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (μ-GPS), vs. Morphine: an analysis of two phase 2 randomized clinical trials. Journal of Pain. 17(4). S82–S83. 2 indexed citations

11.

Viscusi, Eugene R., Lynn R. Webster, Michael E. Kuss, et al.. (2015). A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain. 157(1). 264–272. 169 indexed citations

12.

Bolognese, James A., Ruth Ann Subach, & Franck Skobieranda. (2015). Evaluation of an Adaptive Maximizing Design Study Based on Clinical Utility Versus Morphine for TRV130 Proof-of-Concept and Dose-Regimen Finding in Patients With Postoperative Pain After Bunionectomy. Therapeutic Innovation & Regulatory Science. 49(5). 756–766. 1 indexed citations

13.

Soergel, David G., Ruth Ann Subach, Nancy Burnham, et al.. (2014). Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. 155(9). 1829–1835. 220 indexed citations

14.

Soergel, David G., Ruth Ann Subach, Ian E. James, et al.. (2013). TRVO27, A BETA-ARRESTIN BIASED LIGAND AT THE ANGIOTENSIN 2 TYPE 1 RECEPTOR, PRODUCES RAPID, REVERSIBLE CHANGES IN HEMODYNAMICS IN PATIENTS WITH STABLE SYSTOLIC HEART FAILURE. Journal of the American College of Cardiology. 61(10). E683–E683. 12 indexed citations

15.

Soergel, David G., Ruth Ann Subach, Conrad L. Cowan, Jonathan D. Violin, & Michael W. Lark. (2013). First Clinical Experience with TRV027: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers. The Journal of Clinical Pharmacology. 53(9). 892–899. 68 indexed citations

16.

Soergel, David G., Ruth Ann Subach, Jonathan D. Violin, et al.. (2013). First Human Dosing Experience with TRV130, a Biased Ligand at the Mu Opioid Receptor (P02.013). Neurology. 80(7_supplement). 1 indexed citations

17.

Soergel, David G., Ruth Ann Subach, Brian M. Sadler, et al.. (2013). First Clinical Experience With TRV130: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers. The Journal of Clinical Pharmacology. 54(3). 351–357. 103 indexed citations

18.

Subach, Ruth Ann & Michael Marx. (2002). EVALUATION OF UREMIC PRURITUS AT AN OUTPATIENT HEMODIALYSIS UNIT. Renal Failure. 24(5). 609–614. 17 indexed citations

19.

Subach, Ruth Ann & Sameh R. Abul‐Ezz. (1999). Case Report: Religious Reasons for Discontinuation of Immunosuppressive Medications After Renal Transplant. Renal Failure. 21(2). 223–226. 13 indexed citations

20.

Subach, Ruth Ann & Michael Marx. (1998). Drug Dosing in Acute Renal Failure: The Role of Renal Replacement Therapy in Altering Drug Pharmacokinetics. Advances in Renal Replacement Therapy. 5(2). 141–147. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact